Candel Therapeutics, Inc. Common Stock
CADLCandel Therapeutics, Inc. (CADL) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for the treatment of cancer. The company leverages its proprietary oncolytic viral platform to design and develop therapies aimed at stimulating the immune system to recognize and destroy tumors, with a focus on translating these therapies into effective solutions for patients with various types of cancer.
Company News
Candel Therapeutics presented three key research presentations at SITC 2025, highlighting advances in immunotherapy for solid tumors using multi-omics analysis and artificial intelligence, including promising phase 3 clinical trial results for CAN-2409 in prostate cancer and preclinical data from their enLIGHTENâ„¢ Discovery Platform.
Candel Therapeutics' Interim Chief Financial Officer Charles Schoch sold over $63,000 worth of company stock to cover tax withholding obligations related to the vesting of restricted stock units. The transaction indicates continued investment in the company's future.
Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company's first-quarter EPS was 52 cents, missing the consensus of 53 cents...
